Targeting Therapies: Exploring the Cultural and Normative Dimensions of 'Targeted' Approaches to Biomedicine and Public Health

靶向治疗:探索生物医学和公共卫生“靶向”方法的文化和规范维度

基本信息

  • 批准号:
    AH/W011417/1
  • 负责人:
  • 金额:
    $ 3.77万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    未结题

项目摘要

The Republic of Ireland (RoI) and the United Kingdom (UK) are leaders in biomedicine and public health. Both emphasise the importance of therapeutic innovation for economies and the health of populations. In particular, the RoI and UK have committed, symbolically and financially, to 'targeted' approaches in healthcare research and delivery. By these, we mean for instance: drugs aimed at very specific kinds of disease (e.g. certain cancers) which might respond only to people with particular genetic variants; psychological therapy services tailored to specific kinds of populations (e.g. ex-armed forces personnel); and, population-level interventions that stratify and construct publics in response to existing and emerging forms of illness (e.g. restrictions on the movements of groups regarded as highly vulnerable to COVID-19). At the same time as similarities between the RoI and UK provides a substrate for comparative work, differences exist in the values and norms underlying intervention development and delivery. These divergences could become more pronounced following differential responses to COVID-19 and in light of Brexit. Examining them in relation to the design, delivery, and implications of 'targeted' biomedicine and public health will help us to better understand the dynamics between science, healthcare, and society. We will take cues from existing work on, for instance, personalised and precision (bio)medicine and move in exciting new directions. While research from the humanities on biomedicine and public health often keeps these domains apart, our analysis will seek to look at the commonalities between them.Our Network will draw together approaches from bioethics, gender studies, history, law, medical humanities, political philosophy, and science studies (among others) to explore the cultural and normative dimensions of 'targeted' approaches and interventions in biomedicine and public health. Through comparative analysis, we will explore how different cultural, historical, legal, scientific, and healthcare contexts interact in the shaping and deployment of 'targeted' biomedicine and public health. In other words, we will look at how societal histories, traditions, and legal processes affects how scientific research is funded and conducted, and how healthcare is prioritised and delivered. In turn, we will examine how law, ethics, and cultures are impacted and contoured through targeted approaches to health. Our work-plan has been designed to foster new relationships between and across the investigators (who have not previously worked together), collaborators, wider Network members, and other stakeholders in the RoI and UK (e.g. other humanities scholars, biomedical and public health scientists, life sciences industry, patient groups, wider publics). These relationships will be scaffolded by and enhanced through five Network workshops and associated public engagement. Central to the success of the Network and its capacity-building is the intellectual and financial support that will be provided to humanities ECRs in the RoI and UK in the form of mentorship, opportunities to present their research, introductions to (non-)academic networks, and more.Outputs from the Network will include peer-reviewed papers aimed at different humanities audiences. We will also seek to engage policymakers with our work, as well as biomedical and public health scientists and healthcare professionals (e.g. through invitations to workshops, engagement events, and one-to-one meetings). The investigators are committed to engagement with wider publics, and will achieve this through (e.g.) public-facing blogs, and public panel discussions and similar events associated with the Network workshops. The resources of Edinburgh's Wellcome Trust-supported Centre for Biomedicine, Self & Society will be drawn upon to add value to engagement activities.
爱尔兰共和国(RoI)和联合王国(UK)是生物医学和公共卫生领域的领导者。两者都强调了治疗创新对经济和人口健康的重要性。特别是,爱尔兰共和国和联合王国已经承诺,象征性和财政,在医疗保健研究和提供的“有针对性的”方法。例如,我们指的是针对特定疾病的药物(例如某些癌症),这些疾病可能只对具有特定遗传变异的人有反应;针对特定类型的人群提供心理治疗服务(例如前武装部队人员);并且,在本发明中,人口层面的干预措施,根据现有和新出现的疾病形式对公众进行分层和构建(例如,限制被视为极易感染COVID-19的群体的行动)。与此同时,由于RoI和联合王国之间的相似之处为比较工作提供了基础,但在干预措施的制定和实施所依据的价值观和规范方面存在差异。在对COVID-19的不同反应和英国退欧之后,这些差异可能会变得更加明显。研究它们与“有针对性的”生物医学和公共卫生的设计,交付和影响的关系将有助于我们更好地理解科学,医疗保健和社会之间的动态。我们将从现有的工作中获得线索,例如,个性化和精确(生物)医学,并朝着令人兴奋的新方向发展。虽然生物医学和公共卫生的人文学科研究往往将这些领域分开,但我们的分析将寻求它们之间的共性。我们的网络将汇集生物伦理学,性别研究,历史,法律,医学人文,政治哲学,和科学研究(除其他外),以探讨生物医学和公共卫生领域“有针对性”的方法和干预措施的文化和规范层面。通过比较分析,我们将探索不同的文化,历史,法律的,科学和医疗保健背景如何在“有针对性的”生物医学和公共卫生的塑造和部署中相互作用。换句话说,我们将研究社会历史,传统和法律的程序如何影响科学研究的资助和进行,以及如何优先考虑和提供医疗保健。反过来,我们将研究法律,道德和文化是如何通过有针对性的健康方法的影响和轮廓。我们的工作计划旨在促进研究者(以前没有一起工作过),合作者,更广泛的网络成员以及RoI和英国的其他利益相关者(例如其他人文学者,生物医学和公共卫生科学家,生命科学行业,患者团体,更广泛的公众)之间的新关系。这些关系将通过五个网络讲习班和相关的公众参与得到加强。该网络的成功及其能力建设的核心是将以导师制、展示其研究的机会、介绍(非)学术网络等形式向爱尔兰共和国和联合王国的人文学科ECR提供智力和财政支持。该网络的产出将包括针对不同人文学科受众的同行评审论文。我们还将寻求让政策制定者参与我们的工作,以及生物医学和公共卫生科学家和医疗保健专业人员(例如,通过邀请参加研讨会,参与活动和一对一会议)。调查人员致力于与更广泛的公众接触,并将通过(例如)面向公众的博客、公共小组讨论和与网络讲习班有关的类似活动。爱丁堡的惠康信托基金支持的生物医学,自我与社会中心的资源将被利用,以增加参与活动的价值。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Infrastructuring Educational Genomics: Associations, Architectures, and Apparatuses
教育基因组学基础设施:关联、架构和设备
Stalling or oiling the engines of diagnosis? Shifting perspectives on the DSM and categorical diagnosis in psychiatry.
熄火或给诊断引擎加油?
  • DOI:
    10.1111/1467-9566.13682
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Pickersgill M
  • 通讯作者:
    Pickersgill M
Handbook on the Sociology of Health and Medicine
健康与医学社会学手册
  • DOI:
    10.4337/9781839104756.00043
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Pickersgill M
  • 通讯作者:
    Pickersgill M
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martyn Pickersgill其他文献

Martyn Pickersgill的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martyn Pickersgill', 18)}}的其他基金

Biomedicine and Beyond: The Social and Regulatory Dimensions of Therapeutics in Japan and the UK
生物医学及其他:日本和英国治疗学的社会和监管层面
  • 批准号:
    ES/S013873/1
  • 财政年份:
    2019
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Research Grant

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Exploring novel diagnostic biomarkers and therapies for necrotising enterocolitis in preterm neonates
探索早产儿坏死性小肠结肠炎的新型诊断生物标志物和疗法
  • 批准号:
    2884813
  • 财政年份:
    2023
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Studentship
Exploring mitochondrialflux and lipid compartmentation in vivo to develop new therapies for alcoholic liver disease
探索体内线粒体流和脂质区室以开发酒精性肝病的新疗法
  • 批准号:
    10620346
  • 财政年份:
    2022
  • 资助金额:
    $ 3.77万
  • 项目类别:
Exploring mitochondrialflux and lipid compartmentation in vivo to develop new therapies for alcoholic liver disease
探索体内线粒体流和脂质区室以开发酒精性肝病的新疗法
  • 批准号:
    10451071
  • 财政年份:
    2022
  • 资助金额:
    $ 3.77万
  • 项目类别:
Exploring Novel Therapies in Optic Neuritis
探索视神经炎的新疗法
  • 批准号:
    22K09784
  • 财政年份:
    2022
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Exploring novel combinatorial therapies for personalized management of Cystic Fibrosis using primary human airway epithelial cells
探索利用原代人气道上皮细胞个性化治疗囊性纤维化的新型组合疗法
  • 批准号:
    439577
  • 财政年份:
    2020
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Studentship Programs
Exploring steroid-based therapies to reduce opioid abuse
探索基于类固醇的疗法以减少阿片类药物滥用
  • 批准号:
    9916192
  • 财政年份:
    2020
  • 资助金额:
    $ 3.77万
  • 项目类别:
Exploring Alternative iPS Cell Therapies for Recessive Dystrophic Epidermolysis Bullosa
探索隐性营养不良性大疱性表皮松解症的替代 iPS 细胞疗法
  • 批准号:
    9811321
  • 财政年份:
    2019
  • 资助金额:
    $ 3.77万
  • 项目类别:
Exploring the Real-World Value of Targeted Therapies in Lung Cancer
探索肺癌靶向治疗的现实价值
  • 批准号:
    407508
  • 财政年份:
    2019
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Fellowship Programs
Exploring novel therapies on the basis of pathophysiological commonality between irritable bowel syndrome and metabolic syndrome
基于肠易激综合征和代谢综合征之间的病理生理学共性探索新疗法
  • 批准号:
    18K07896
  • 财政年份:
    2018
  • 资助金额:
    $ 3.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalizing COPD therapies by exploring heterogeneity of treatment effects
通过探索治疗效果的异质性来个性化慢性阻塞性肺病治疗
  • 批准号:
    9267162
  • 财政年份:
    2016
  • 资助金额:
    $ 3.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了